Mariano F. Zacarías-Fluck, PhD

Year of birth: 1976

Nationalities: Argentine and German

Residence: Barcelona, Spain

LinkedIn Profile

Profile

Senior research scientist with 25 years of experience in international, multicultural projects from concept to delivery. Expert in experimental design, data analysis, and development of innovative research tools. Secured €0.5M in funding, authored two patents, and published 20 peer-reviewed papers.

Professional Experience

Models of Cancer Therapies Laboratory, Vall d’ Hebron Institute of Oncology (VHIO), Barcelona, Spain.

  • Senior Researcher. 2025 – present.

  • Research Associate. 2020 – 2024.

  • Senior Postdoctoral Researcher. 2016 – 2019.

Growth Factors Laboratory, VHIO.

  • Postdoctoral Researcher. 2010 – 2015.

Institute for Experimental Genetics, School of Medical Sciences, National University of Rosario (UNR), Argentina.

  • Ph.D. candidate. 2005 – 2010

  • Undergraduate student. 2001 – 2005

Experience by Functional Areas

Project management

Project design, development, execution plan, and writing of reports.

Design and writing of two grant proposals for three-year projects, including all aspects (financial, resource planning, execution), funded by Spanish Ministry of Science, Innovation and Universities.

Involved in the writing and/or development of other projects.

Coordinator of technicians involved in the projects.

International collaboration. Published papers in collaboration with research groups from Europe, the Americas and Asia.

Research & Experimental Leadership (Development of research/analysis resources)

  • Hypothesis-driven planning, organisation, agile and dynamic coordination, execution and support of in vivo and in vitro experiment.

  • Mouse colony management sustaining the execution of my experimental plan.

  • Development of bioinformatic pipelines and data visualisation strategies.

  • Generation of cancer cell lines: resistant to standard-of-care treatments, derived from spontaneous metastases in mice, and from patient-derived xenografts.

  • Generation of mouse models of lymphoma.

Data Analysis:

  • Bioinformatic analysis in R, interpretation and visualisation of data.

  • Statistical, biomedical, and bioinformatic analysis and interpretation of data.

Scientific Output & Dissemination

  • Authored 20 scientific papers: ORCID link.

  • Publications metrics (Web of Science): H-Index: 10, sum of times cited: 679.

  • Edition of books and special issues:

    • 2026 The MYC Gene – Methods and Protocols, 3rd edition. Soucek, Zacarías-Fluck, eds. Springer Nature. In preparation.

    • 2024 MYC as a disease target beyond cancer. Whitfield, Zacarias-Fluck, et al.

  • Presentations in scientific meetings: 35 in Argentina, Spain, USA, Germany, Poland.

  • Holder of two patents in biomedicine:

    • 2023 Combination Therapy with BRAF Inhibitors for the Treatment of Cancer.

    • 2023 Combination Therapy with MEK Inhibitors for the Treatment of Cancer.

Mentorship: three: a medicine student, a Ph.D. student and a M.Sc. student.

Teaching, five courses, for undergraduate and Ph.D. students.

Education

Ph.D. in Biomedical Sciences

2006 – 2010 School of Medical Sciences, UNR. Thesis: “Regulation of Galectin-1 expression in lymphoma and its relationship with tumour growth and immune response”.

Degree in Biotechnology

1996 – 2005 School of Pharmaceutical and Biochemical Sciences, UNR. Thesis: “Dynamics and modulation of Galectin-1 expression in a rat lymphoma model treated with a low dose of Cyclophosphamide”.

Languages: Spanish (native speaker), English C1, German B1, Catalan A2

Other studies: Music Composition (three years of pre-University studies and three years of higher education at the UNR), intermittently from 1996 to 2008.

Honours and awards

Skills and interests

  • Strong background in translational oncology research, Data Visualisation.

  • Excellent communication and presentation skills in English and Spanish.

  • Robust writing skills.

  • Working in culturally diverse research groups to define objectives, methodologies and draw conclusions. Receptive and good listener.

  • Encouraging critical thinking and discussion.

  • IT skills: Intermediate knowledge of R programming, Fiji/ImageJ, Inkscape. Advanced knowledge of Microsoft Office Suite and GraphPad Prism.

  • Interests: Genealogy (20+ experience as a researcher), Paleogenetics.

References

International collaboration

  • Europe: Brunel University of London and University of Cambridge, UK; Karolinska Institutet, Sweden; Institut Curie, France; Novartis Pharma, Switzerland.

  • Americas: School of Medical Sciences, National University of Rosario, and Instituto de Biología y Medicina Experimental (IBYME-CONICET), Argentina; McMaster Children's Hospital, Ontario and Hospital for Sick Children, Toronto, Canada; University of California, CA, USA.

  • Asia: Duke-National University of Singapore (NUS) Medical School, Singapore.

Participation in funded projects

As a Senior Researcher

  • 2026 — 2029. Proyectos de Generación de Conocimiento 2024. Investigación Orientada Tipo B. Descifrando la resistencia al tratamiento del cancer: inhibicion de myc como estrategia terapeutica para mejorar la eficacia del tratamiento. PID2024-156280OB-I00. PI: Laura Soucek

  • 2026 — 2029. Acción Estratégica en Salud - Líneas Estratégicas de Investigación en Salud (AES-LEIS 2024 — 2027). PI25/00881 “MYC inhibition as a strategy to disarm BRAFi resistance”. PI: Laura Soucek, co-PI: Mariano F. Zacarías-Fluck

  • 2024 — 2029. European Research Council — 2023-Advanced Grant. Proposal number: 101142260. Proposal acronym: MYCiMAX. PI: Laura Soucek

  • 2023 — 2026. Proyectos de Colaboración Público-Privada. Project Coordinator: Dr. Marie-Eve Beaulieu. Clinical proof-of-concept of a first-in-class MYC inhibitor in combination therapy and expansion of its development plan (CLINIMYC)

  • 2021 — 2025. Proyectos de I+D+i en líneas estratégicas, en colaboración público-privada 2021. PLEC2021-007959. Uso de la inhibición de MYC para superar la resistencia a la inmunoterapia en nsclc impulsado por kras con diversos perfiles mutacionales (MYCOMBIO). Líder del consorcio: Peptomyc S.L., PARTICIPANTES: Peptomyc S.L., Vall D’Hebron Institute of Oncology (VHIO), Centro de Investigación Médica Aplicada (CIMA) y Hospital Universitario 12 de Octubre (HU12O).

As a Research Associate

  • 2024 — 2029. European Research Council — 2023-Advanced Grant. Proposal number: 101142260. Proposal acronym: MYCiMAX. PI: Laura Soucek

  • 2023 — 2026. Proyectos de Colaboración Público-Privada. Project Coordinator: Dr. Marie-Eve Beaulieu. Clinical proof-of-concept of a first-in-class MYC inhibitor in combination therapy and expansion of its development plan (CLINIMYC)

  • 2023 — 2024. Premio Chiara Giorgetti 2022. Combining MYC and PARP inhibitors as a novel therapeutic strategy against triple-negative breast cancer.

  • 2022. AGAUR. Suport a Grups de Recerca (SGR 2021.01509)

  • 2021 — 2025. Proyectos de I+D+i en líneas estratégicas, en colaboración público-privada 2021. PLEC2021-007959. Uso de la inhibición de MYC para superar la resistencia a la inmunoterapia en nsclc impulsado por kras con diversos perfiles mutacionales (MYCOMBIO). Líder del consorcio: Peptomyc S.L., PARTICIPANTES: Peptomyc S.L., Vall D’Hebron Institute of Oncology (VHIO), Centro de Investigación Médica Aplicada (CIMA) y Hospital Universitario 12 de Octubre (HU12O).

  • 2020 — 2023. La Marató de TV3. Overcoming immunotherapeutic resistance through Myc inhibition in KRas-driven NSCLC with diverse mutational landscape (474/C/2019). PI: Dr. Laura Soucek.

  • 2020 — 2024. Proyectos de investigación en salud (AES 2019). Modalidad proyectos en salud. PI19/01277 “Validation of new anti-Myc therapy in Melanoma”. PI: Laura Soucek.

Mentorship

  1. “Characterisation of MYC inhibition effect on the resistance to targeted therapies against melanoma”. Manuel Lillo Valero, M.Sc. Degree in Translational Biomedical Research Course 2023-2024. Co-directed with Dr. Laura Soucek. VHIO. Qualification: 9.5/10.

  2. Mentorship of Ph.D. student Junjie Zhang during his first year at the Growth Factors Laboratory, VHIO. 2014.

  3. “Obtainment of a lower growth rate variant of L-DGE murine lymphoma through bifurcating selection based on tumour growth. Analysis of the response to low doses of Cyclophosphamide”, Leonardo Hess Medicine Undergraduate Project. Co-directed with Dr. O.G. Sharovsky, Institute of Experimental Genetics, School of Medical Sciences, UNR, Argentina.

Teaching

  • 2007 — 2010 Teaching Assistant (Category 1) in Molecular Biology, School of Biochemical and Pharmaceutical Sciences, UNR.

  • 2008 “Molecular technics for the diagnostic and follow-up of cancer patients”. Class from PhD in Biomedical Sciences course “Cellular and Molecular Oncology”. School of Medical Sciences, UNR.

  • 2007 “Assessment of microbiological risk. Basic laboratories, biosafety levels 1 to 4”. Class from PhD in Biomedical Sciences course “Biosafety” School of Medical Sciences, UNR.

  • 2007 Teaching Assistant in the course “Introduction to Human Genetics”.

  • 2005 — 2007 Teaching Assistant (Category 2, Res. No 361/05 y 454/06) in Molecular Biology, School of Biochemical and Pharmaceutical Sciences, UNR.

Education

Ph.D. in Biomedical Sciences. Institute for Experimental Genetics, School of Medical Sciences, National University of Rosario, Argentina. 2010.

Thesis: “Regulation of Galectin-1 expression in lymphoma and its relationship with tumour growth and immune response”. Mentors: Dr. O. Graciela Scharovsky and Dr. Gabriel A. Rabinovich. Main subjects covered:

  • Experimental design and statistical analysis of the results.

  • Cell culture of tumours and splenocytes.

  • In vivo experiments in rat and mouse models of lymphoma.

  • Molecular biology technics to analyse the expression and localisation of the proteins of interest: western blot, immunohistochemistry, flow cytometry, PCR, ELISA.

  • Mouse colony management.

Ph.D. courses:

  • Logics.

  • Rat surgery.

  • Laboratory Animals in Scientific Research.

  • Immunity, tolerance and cancer. From immunosurveillance to tumour escape.

  • Biostatistics II.

  • Immunology.

  • Epistemology and Methodology of Research.

Degree in Biotechnology (5 years). Institute for Experimental Genetics, Rosario, Argentina. 2005.

Undergraduate Thesis: “Dynamics and modulation of Galectin-1 expression in a rat lymphoma model treated with a low dose of Cyclophosphamide”. Director: Dr. OG Scharovsky.

Additional courses taken:

  • Genetics and Biometrics. Monograph “Regulation of gene expression through nucleic acids”

  • Principles and applications of RNA interference (siRNA)

  • Biostatistics

  • Monoclonal antibodies

  • Molecular and Cellular Oncology Bases